Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study
2024

CD24 Expression in Prostate Cancer vs. Benign Prostatic Hyperplasia

Sample size: 163 publication Evidence: high

Author Information

Author(s): Sajedifar Mahdi, Jafarabadi Ashtiani Atieh, Jalali Nadoushan Mohammadreza

Primary Institution: Shahed University, Tehran, Iran

Hypothesis

This study aims to investigate the relationship between immunohistochemical expression of CD24 and its relationship with benign prostatic hyperplasia and Gleason grade in prostate adenocarcinoma.

Conclusion

CD24 expression can help differentiate prostate adenocarcinoma from benign prostatic hyperplasia and indicates the progression of prostate cancer.

Supporting Evidence

  • CD24 expression percentage and staining intensity were significantly higher in prostate adenocarcinoma patients than in BPH patients.
  • Gleason grade strongly correlated with the percentage and intensity of CD24 staining.
  • An immunoreactive score of more than 100 was reported in 33.3% of prostate adenocarcinoma patients and 0% of BPH patients.

Takeaway

This study found that a protein called CD24 is more common in prostate cancer than in benign prostate conditions, which can help doctors tell the difference between the two.

Methodology

A cross-sectional study involving 163 patients, using immunohistochemical staining to evaluate CD24 expression and analyzing data with SPSS.

Participant Demographics

163 male patients with an average age of 70.63 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.30699/ijp.2024.2021959.3251

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication